Home
- Novel proprietary adjuvant system relying on the use of anti-CD40 antibodies
- Novel mode of action may allow the system to be used in combination with other adjuvants and in situations where existing systems don't work
- Proof of concept achieved in pre-clinical studies
- Interested in partnering for vaccine development and to source anti CD40
